{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:00:56Z","timestamp":1792098056594,"version":"4.4.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,12,1]],"date-time":"2008-12-01T00:00:00Z","timestamp":1228089600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2008,12]]},"DOI":"10.1016\/j.ajo.2008.08.038","type":"journal-article","created":{"date-parts":[[2008,11,22]],"date-time":"2008-11-22T04:27:30Z","timestamp":1227328050000},"page":"837-844.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":123,"title":["Long-term Efficacy and Safety of Low-dose Interferon Alpha2a Therapy in Severe Uveitis Associated With Beh\u00e7et Disease"],"prefix":"10.1016","volume":"146","author":[{"given":"Julie","family":"Gueudry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Wechsler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Terrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00ebl","family":"Gendron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cassoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Fardeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phuc","family":"Lehoang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Piette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajo.2008.08.038_bib1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.survophthal.2005.04.009","article-title":"Current concepts in the etiology and treatment of Beh\u00e7et disease","volume":"50","author":"Evereklioglu","year":"2005","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib2","first-page":"529","article-title":"Ocular manifestations of Beh\u00e7et's disease","volume":"150","author":"Cassoux","year":"1999","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.ajo.2008.08.038_bib3","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A double-blind trial of colchicine in Beh\u00e7et's syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajo.2008.08.038_bib4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1056\/NEJM199002013220501","article-title":"A controlled trial of azathioprine in Beh\u00e7et's syndrome","volume":"322","author":"Yazici","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2008.08.038_bib5","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Beh\u00e7et's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2008.08.038_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/00004397-199603610-00013","article-title":"Diagnosis and ophthalmological features of Beh\u00e7et's disease","volume":"36","author":"Bhisitkul","year":"1996","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.ajo.2008.08.038_bib7","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S0021-5155(99)00029-5","article-title":"Epidemiological features and visual prognosis of Beh\u00e7et's disease","volume":"43","author":"Ando","year":"1999","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib8","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ophtha.2003.07.018","article-title":"Comparison of patients with Beh\u00e7et's disease in the 1980s and 1990s","volume":"111","author":"Yoshida","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2008.08.038_bib9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.ajo.2004.03.022","article-title":"Uveitis in Beh\u00e7et disease: an analysis of 880 patients","volume":"138","author":"Tugal-Tutkun","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib10","first-page":"343","article-title":"Ocular prognosis in Beh\u00e7et's disease","volume":"15","author":"Cochereau-Massin","year":"1992","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib11","first-page":"592","article-title":"Ophthalmological involvement in Beh\u00e7et disease","volume":"20","author":"El Belhadji","year":"1997","journal-title":"J Fr Ophtalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib12","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S0161-6420(03)00406-8","article-title":"Infliximab in the treatment of refractory posterior uveitis","volume":"110","author":"Joseph","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2008.08.038_bib13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/bjo.2003.037192","article-title":"Anti-TNF-alpha therapy for sight threatening uveitis","volume":"89","author":"Lindstedt","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib14","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0161-6420(03)00721-8","article-title":"Tumor necrosis factor? blockade with infliximab for refractory uveitis and scleritis","volume":"111","author":"Murphy","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2008.08.038_bib15","first-page":"1362","article-title":"Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis","volume":"31","author":"Ohno","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajo.2008.08.038_bib16","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(01)05497-6","article-title":"Effect of infliximab on sight-threatening panuveitis in Beh\u00e7et's disease","volume":"358","author":"Sfikakis","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2008.08.038_bib17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/archopht.123.7.903","article-title":"A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes","volume":"123","author":"Suhler","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib18","first-page":"S14","article-title":"Infliximab in refractory uveitis due to Beh\u00e7et's disease","volume":"22","author":"Wechsler","year":"2004","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.ajo.2008.08.038_bib19","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajo.2008.08.038_bib20","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajo.2008.08.038_bib21","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","article-title":"Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial","volume":"354","author":"Maini","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2008.08.038_bib22","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1128\/jcm.34.5.1321-1322.1996","article-title":"Stability of amoxicillin-clavulanate in BACTEC medium determined by high-performance liquid chromatography and bioassay","volume":"34","author":"Moore","year":"1996","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ajo.2008.08.038_bib23","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1016\/S0140-6736(94)92549-6","article-title":"Interferon-alpha 2b for refractory ocular Beh\u00e7et's disease","volume":"343","author":"Feron","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2008.08.038_bib24","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/bjo.82.5.488","article-title":"Treatment of ocular symptoms of Beh\u00e7et's disease with interferon-alpha 2a: a pilot study","volume":"82","author":"Kotter","year":"1998","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib25","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1600-0420.1997.tb00638.x","article-title":"Interferon-alpha for ocular Beh\u00e7et's disease","volume":"75","author":"Pivetti-Pezzi","year":"1997","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ajo.2008.08.038_bib26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","article-title":"Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients","volume":"91","author":"Bodaghi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib27","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/kem199","article-title":"Efficacy and safety of interferon-{alpha} in the treatment of corticodependent uveitis of paediatric Beh\u00e7et's disease","volume":"46","author":"Guillaume-Czitrom","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.ajo.2008.08.038_bib28","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon alpha in Beh\u00e7et disease: review of the literature","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.ajo.2008.08.038_bib29","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","article-title":"Results of interferon-alfa therapy in patients with Beh\u00e7et uveitis","volume":"244","author":"Tugal-Tutkun","year":"2006","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib30","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1076\/ocii.8.4.293.6453","article-title":"Efficacy of interferon-alfa-2a in severe and refractory uveitis associated with Beh\u00e7et's disease","volume":"8","author":"Wechsler","year":"2000","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ajo.2008.08.038_bib31","first-page":"1078","article-title":"Criteria for diagnosis of Beh\u00e7et's disease","volume":"335","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2008.08.038_bib32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0002-9394(14)74235-7","article-title":"International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease","volume":"103","author":"Bloch-Michel","year":"1987","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib33","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","article-title":"Standardization of uveitis nomenclature for reporting clinical data","volume":"140","author":"Jabs","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib34","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1001\/archderm.138.4.467","article-title":"Interferon-alfa-2a in the treatment of Beh\u00e7et disease: a randomized placebo-controlled and double-blind study","volume":"138","author":"Alpsoy","year":"2002","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ajo.2008.08.038_bib35","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/0-306-48382-3_102","article-title":"The use of interferon-alpha in Beh\u00e7et's disease\u2013review of the literature and possible mechanisms of action","volume":"528","author":"Kotter","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ajo.2008.08.038_bib36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/0-306-48382-3_103","article-title":"Interferon-alfa-2a in the treatment of ocular Adamantiades-Beh\u00e7et's disease","volume":"528","author":"Krause","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ajo.2008.08.038_bib37","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1001\/archderm.134.8.1010","article-title":"Treatment of Adamantiades-Beh\u00e7et disease with systemic interferon-alfa","volume":"134","author":"Zouboulis","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.ajo.2008.08.038_bib38","first-page":"1938","article-title":"Interferon-alpha treatment of Beh\u00e7et's disease","volume":"25","author":"O'Duffy","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajo.2008.08.038_bib39","first-page":"293","article-title":"The use of interferon- alfa-2r in the treatment of autoimmune uveitis (primary or associated with Beh\u00e7et's disease)","volume":"196","author":"Sanchez Roman","year":"1996","journal-title":"Rev Clin Esp"},{"key":"10.1016\/j.ajo.2008.08.038_bib40","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.iae.0000244265.75771.71","article-title":"Interferon-alfa-2a: a new treatment option for long-lasting refractory cystoid macular edema in uveitis?","volume":"26","author":"Deuter","year":"2006","journal-title":"Retina"},{"key":"10.1016\/j.ajo.2008.08.038_bib41","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2007.03.050","article-title":"Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis","volume":"144","author":"Plskova","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib42","first-page":"1633","article-title":"Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Beh\u00e7et's disease: focusing more on IFN","volume":"32","author":"Kotter","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ajo.2008.08.038_bib43","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","article-title":"Human recombinant interferon alfa-2a for the treatment of Beh\u00e7et's disease with sight threatening posterior or panuveitis","volume":"87","author":"Kotter","year":"2003","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib44","first-page":"136","article-title":"Evaluation of conventional therapy versus cyclosporine A in Beh\u00e7et's syndrome","volume":"20","author":"BenEzra","year":"1988","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ajo.2008.08.038_bib45","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/art.1780280611","article-title":"Effectiveness of cyclosporin therapy for Beh\u00e7et's disease","volume":"28","author":"Nussenblatt","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.ajo.2008.08.038_bib46","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1136\/bjo.76.4.241","article-title":"Low-dose cyclosporin A versus pulsed cyclophosphamide in Beh\u00e7et's syndrome: a single masked trial","volume":"76","author":"Ozyazgan","year":"1992","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.ajo.2008.08.038_bib47","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1034\/j.1600-0420.1998.760118.x","article-title":"Cyclosporin-A therapy in severe uveitis of Beh\u00e7et's disease","volume":"76","author":"Sullu","year":"1998","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.ajo.2008.08.038_bib48","first-page":"928","article-title":"Interferon-alfa combined with azathioprine for the uveitis of Beh\u00e7et's disease: an open study","volume":"4","author":"Hamuryudan","year":"2002","journal-title":"Isr Med Assoc J"},{"key":"10.1016\/j.ajo.2008.08.038_bib49","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1200\/JCO.1986.4.2.234","article-title":"Clinical toxicity of interferons in cancer patients: a review","volume":"4","author":"Quesada","year":"1986","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ajo.2008.08.038_bib50","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0161-6420(02)01741-4","article-title":"Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin","volume":"110","author":"Schulman","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2008.08.038_bib51","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/S0168-8278(02)00243-X","article-title":"Visual loss during interferon-alpha therapy in hepatitis C virus infection","volume":"37","author":"Perlemuter","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.ajo.2008.08.038_bib52","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/S0140-6736(99)00403-1","article-title":"Severe loss of vision during adjuvant interferon-alfa-2b treatment for malignant melanoma","volume":"353","author":"Lohmann","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ajo.2008.08.038_bib53","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1038\/sj.eye.6702352","article-title":"Adalimumab for sight-threatening uveitis in Beh\u00e7et's disease","volume":"21","author":"Mushtaq","year":"2007","journal-title":"Eye"},{"key":"10.1016\/j.ajo.2008.08.038_bib54","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/rheumatology\/kem034","article-title":"Anti-TNF therapy in the management of Beh\u00e7et's disease\u2013review and basis for recommendations","volume":"46","author":"Sfikakis","year":"2007","journal-title":"Rheumatology (Oxford)"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293940800696X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000293940800696X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T12:57:55Z","timestamp":1757595475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000293940800696X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":54,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S000293940800696X"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2008.08.038","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2008,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term Efficacy and Safety of Low-dose Interferon Alpha2a Therapy in Severe Uveitis Associated With Beh\u00e7et Disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2008.08.038","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}